CN115515595A - 用于治疗乙肝的组合 - Google Patents

用于治疗乙肝的组合 Download PDF

Info

Publication number
CN115515595A
CN115515595A CN202180034220.4A CN202180034220A CN115515595A CN 115515595 A CN115515595 A CN 115515595A CN 202180034220 A CN202180034220 A CN 202180034220A CN 115515595 A CN115515595 A CN 115515595A
Authority
CN
China
Prior art keywords
combination
combination according
compound
optionally substituted
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180034220.4A
Other languages
English (en)
Inventor
蔡哲
孙飞
胡彦宾
丁照中
陈曙辉
吴文强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujian Guangsheng Zhonglin Biotechnology Co ltd
Original Assignee
Fujian Guangsheng Zhonglin Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Guangsheng Zhonglin Biotechnology Co ltd filed Critical Fujian Guangsheng Zhonglin Biotechnology Co ltd
Publication of CN115515595A publication Critical patent/CN115515595A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明涉及一类用于治疗乙型肝炎的式(I)所示化合物与其他治疗乙型肝炎药物的组合，以及该组合在制备治疗乙型肝炎药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (32)

  1. PCT国内申请，权利要求书已公开。
CN202180034220.4A 2020-05-15 2021-05-14 用于治疗乙肝的组合 Pending CN115515595A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020104127717 2020-05-15
CN202010412771 2020-05-15
PCT/CN2021/093805 WO2021228222A1 (zh) 2020-05-15 2021-05-14 用于治疗乙肝的组合

Publications (1)

Publication Number Publication Date
CN115515595A true CN115515595A (zh) 2022-12-23

Family

ID=78525330

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180034220.4A Pending CN115515595A (zh) 2020-05-15 2021-05-14 用于治疗乙肝的组合

Country Status (5)

Country Link
US (1) US20230183263A1 (zh)
EP (1) EP4151220A4 (zh)
JP (1) JP2023526345A (zh)
CN (1) CN115515595A (zh)
WO (1) WO2021228222A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189643A1 (en) * 2005-02-11 2006-08-24 Huanming Chen Novel heterocyclic compounds having anti-HBV activity
CN108727378A (zh) * 2017-04-19 2018-11-02 银杏树药业(苏州)有限公司 新型异喹啉类化合物及其医药用途
WO2019169539A1 (en) * 2018-03-05 2019-09-12 Pharmaresources (Shanghai) Co., Ltd. Novel oxa-and aza-tricyclic 4-pyridone-3-carboxylic acid for treatment and prophylaxis of hepatitis b virus infection
US20200039995A1 (en) * 2017-03-09 2020-02-06 Fujian Cosunter Pharmaceutical Co., Ltd. Hepatitis b virus surface antigen inhibitor
CN110950860A (zh) * 2018-09-26 2020-04-03 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128335A1 (en) 2015-02-11 2016-08-18 F. Hoffmann-La Roche Ag Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
CA3111792A1 (en) * 2018-09-05 2020-03-12 Children's Medical Center Corporation Papd5 inhibitors and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189643A1 (en) * 2005-02-11 2006-08-24 Huanming Chen Novel heterocyclic compounds having anti-HBV activity
US20200039995A1 (en) * 2017-03-09 2020-02-06 Fujian Cosunter Pharmaceutical Co., Ltd. Hepatitis b virus surface antigen inhibitor
CN108727378A (zh) * 2017-04-19 2018-11-02 银杏树药业(苏州)有限公司 新型异喹啉类化合物及其医药用途
WO2019169539A1 (en) * 2018-03-05 2019-09-12 Pharmaresources (Shanghai) Co., Ltd. Novel oxa-and aza-tricyclic 4-pyridone-3-carboxylic acid for treatment and prophylaxis of hepatitis b virus infection
CN110950860A (zh) * 2018-09-26 2020-04-03 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用

Also Published As

Publication number Publication date
EP4151220A4 (en) 2023-11-15
EP4151220A1 (en) 2023-03-22
US20230183263A1 (en) 2023-06-15
WO2021228222A1 (zh) 2021-11-18
JP2023526345A (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
CN106810548A (zh) 一种二氢异喹啉类化合物
CA3062499C (en) Benzo[f]pyrido[1,2-d][1,4]oxazepine derivatives and pharmaceutical compositions thereof useful as hepatitis b virus surface antigen inhibitor
CN101247807A (zh) 噻唑化合物及使用方法
JP2003510352A (ja) ウイルス媒介性疾病の治療用化合物
CN116615189A (zh) 新型细胞代谢调节化合物及其用于治疗病毒疾病的用途
CN115515595A (zh) 用于治疗乙肝的组合
CN113277994A (zh) 噻唑类化合物及其制备方法和用途
JP7236065B1 (ja) トリアジン誘導体を含有する医薬組成物
US5712282A (en) Method for therapeutically treating tardive dyskinesia and uses thereof
CA2300373A1 (en) Immunomodulator exhibiting antimicrobial and antimycobacterial activities, method for producing the same and pharmaceutical preparation for treating mycobacterioses as well as pulmonary chronic and non-specific conditions, sexually transmitted diseases and the resulting immuno-deficiency
CN113717190B (zh) 一类吲哚生物碱及其药物组合物与其制备方法和应用
CN112368288B (zh) 一种乙肝表面抗原抑制剂的晶型
CN113662945A (zh) 用于治疗乙型肝炎的组合
EP4151221A1 (en) Combination comprising tricycle compound and use thereof in preparation of medicament for treating hbv
CN111655712B (zh) 作为肿瘤免疫类的化合物及其应用
TW202203914A (zh) 特別用於治療b型肝炎和d型肝炎之抗病毒化合物
US9796722B1 (en) Hepatitis B viral assembly effectors
CN114159445B (zh) 筛选抑制新型冠状病毒感染的小分子药物的方法及其应用
CN115197164A (zh) 新型噻唑类化合物及其制备方法和用途
CN116761598A (zh) Fabp4调节化合物的抗病毒用途
CN117126163A (zh) 苯并杂环类化合物及其制备方法和应用
CN114423433A (zh) 包含tlr7激动剂的药物组合
EP3825318A1 (en) Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
CN112028889A (zh) 一种脱氧鸟嘌呤核苷类似物的新晶型
JPH06227982A (ja) 抗ウイルス剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination